Monthly information on share capital and company voting rights
Cellectis (CLLS) has released its monthly share capital and voting rights report as of April 30, 2025. The company reported a total of 100,290,220 shares in its capital structure, with 89,075,490 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.
Cellectis (CLLS) ha pubblicato il suo rapporto mensile sul capitale sociale e sui diritti di voto al 30 aprile 2025. La società ha comunicato un totale di 100.290.220 azioni nella sua struttura di capitale, con 89.075.490 diritti di voto complessivi. Questa comunicazione è effettuata in conformità all'Articolo 223-16 del Regolamento Generale dell'autorità francese dei mercati finanziari, dato che la società è quotata su Euronext Growth.
Cellectis (CLLS) ha publicado su informe mensual sobre el capital social y los derechos de voto a fecha del 30 de abril de 2025. La empresa informó un total de 100.290.220 acciones en su estructura de capital, con 89.075.490 derechos de voto totales. Esta divulgación se realiza de acuerdo con el Artículo 223-16 del Reglamento General de la autoridad financiera francesa, ya que la empresa cotiza en Euronext Growth.
Cellectis (CLLS)는 2025년 4월 30일 기준 월간 자본금 및 의결권 보고서를 발표했습니다. 회사는 자본 구조에 총 100,290,220주의 주식과 89,075,490개의 총 의결권을 보고했습니다. 이 공시는 회사가 유로넥스트 그로스에 상장되어 있어 프랑스 금융시장청 일반 규정 제223-16조에 따라 이루어졌습니다.
Cellectis (CLLS) a publié son rapport mensuel sur le capital social et les droits de vote au 30 avril 2025. La société a déclaré un total de 100 290 220 actions dans sa structure de capital, avec 89 075 490 droits de vote au total. Cette divulgation est effectuée conformément à l'article 223-16 du Règlement Général de l'Autorité des marchés financiers française, la société étant cotée sur Euronext Growth.
Cellectis (CLLS) hat seinen monatlichen Bericht über das Grundkapital und die Stimmrechte zum 30. April 2025 veröffentlicht. Das Unternehmen meldete insgesamt 100.290.220 Aktien in seiner Kapitalstruktur sowie 89.075.490 Stimmrechte. Diese Offenlegung erfolgt gemäß Artikel 223-16 der Allgemeinen Verordnung der französischen Finanzmarktaufsicht, da das Unternehmen an Euronext Growth notiert ist.
- None.
- None.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, May 07, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 04/30/2025 | 100,290,220 | 89,075,490 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
What is the current number of shares outstanding for Cellectis (CLLS) as of April 2025?
How many voting rights does Cellectis (CLLS) have as of April 2025?
Why is there a difference between Cellectis (CLLS) total shares and voting rights?
Where is Cellectis (CLLS) stock listed?
